Pharmacists in Ottumwa, Iowa


29 Pharmacists found in Ottumwa
female pharmacist

Kimberly Robinson, PHARMD


Pharmacist
337 Church St, Ottumwa, IA 52501
641-682-3467    

male pharmacist

Marc Thieme, RPH


Pharmacist
1140 N Jefferson St, Ottumwa, IA 52501
641-684-5467    

female pharmacist

Marcia Anne Celania, RPH


Pharmacist
1140 N Jefferson St, Ottumwa, IA 52501
641-684-5467    



male pharmacist

Dr. Mark Alan Hogan Jr., PHARMD


Pharmacist
1140 N Jefferson St, Ottumwa, IA 52501
641-684-5467     641-683-8364

female pharmacist

Mason Paige Herrick, PHARMD


Pharmacist
1140 N Jefferson St, Ottumwa, IA 52501
641-684-5467     641-683-8364

female pharmacist

Michelle April Moon, PHARMD


Pharmacist
1025 N Quincy Ave Ste 2, Ottumwa, IA 52501
641-683-4483    

female pharmacist

Paula Lynn Waite, RPH


Pharmacist
1940 Venture Dr, Ottumwa, IA 52501
641-919-9025    

male pharmacist

Dr. Robert Louis Cobert, PHARMD


Pharmacist
2453 N Court St, Ottumwa, IA 52501
641-684-1853     641-683-5949

male pharmacist

Dr. Ron Cole Hartman, PHARMD


Pharmacist
107 W Main St, Ottumwa, IA 52501
641-684-5453     641-684-5407

female pharmacist

Shania Wilz, PHARMD


Pharmacist
1527 Albia Rd, Ottumwa, IA 52501
641-244-7076     641-548-5511

female pharmacist

Shavea Noami Zapata Juan, PHARMD


Pharmacist
327 W 4th St, Ottumwa, IA 52501
641-226-5077    

female pharmacist

Talia Kae Parenza, PHARMD.


Pharmacist
2453 N Court St, Ottumwa, IA 52501
641-684-1853     641-683-5949

female pharmacist

Dr. Wendy A Barker, PHARMD


Pharmacist
1025 N Quincy Ave, Ottumwa, IA 52501
641-683-4483    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.